000513:SZSELivzon Pharmaceutical Group Inc. Analysis

Livzon Pharmaceutical (000513.SZ) is trading at roughly 29.3 CNY, a level that sits below its 20‑day, 50‑day and 200‑day moving averages, indicating a bearish price bias. The 14‑day RSI hovers in the mid‑30s, suggesting modest oversold pressure but not yet in extreme territory. MACD remains in a bearish configuration, with the histogram turning negative, reinforcing the short‑term downside momentum. Despite the technical weakness, the stock offers a dividend yield near 5%, supported by a payout ratio of about 50% and ample cash on hand. Valuation metrics are attractive: the price‑to‑earnings multiple is well below the industry average and the discounted cash‑flow model implies a fair value over 36 CNY, representing more than 30% upside.
Revenue has contracted modestly year over year, yet gross and operating margins remain robust, reflecting the company’s diversified product portfolio and strong pricing power. The balance sheet is solid, with cash exceeding three times total debt and a debt‑to‑equity ratio under 20%, providing ample flexibility for dividend payments and potential investments. Volatility is elevated, with a 30‑day range above 28%, while beta is almost negligible, indicating that price swings are driven more by company‑specific factors than broad market moves. Regulatory and geographic exposure is concentrated in China’s pharmaceutical sector, where policy shifts can materially affect earnings, placing the regulatory risk at a higher tier. Overall, the combination of undervaluation, strong cash generation, and a sustainable dividend makes the stock appealing for patient investors, while the near‑term technical outlook advises caution.